Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 8 trials

Late-Stage Pipeline

0 trials in Phase 3/4

Results Transparency

0 of 0 completed trials have results

Key Signals

6 recruiting

Enrollment Performance

Analytics

Early Phase 1

8(100.0%)

8Total

Early Phase 1(8)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (8)

Showing 8 of 8 trials

NCT06171282Early Phase 1Recruiting

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Bone and Soft Tissue Tumors

Role: lead

NCT05961111Early Phase 1Recruiting

A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Advanced Solid Tumors

Role: lead

NCT05886075Early Phase 1Unknown

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Advanced Solid Tumors

Role: lead

NCT05860374Early Phase 1Recruiting

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Advanced Solid Tumors

Role: lead

NCT05851456Early Phase 1Recruiting

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Bone and Soft Tissue Tumors

Role: lead

NCT05830240Early Phase 1Recruiting

A Clinical Study on Oncolytic Virus Injection (R130 OV) for the Treatment of Relapsed/Refractory Head and Neck Cancer

Role: lead

NCT05812677Early Phase 1Recruiting

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Cervical and Endometrial Cancer

Role: lead

NCT05801783Early Phase 1Unknown

A Clinical Study on Oncolytic Virus Injection (R130) for the Treatment of Relapsed/Refractory Ovarian Cancer

Role: lead

All 8 trials loaded